AURORA, Colorado, December 19, 2003 — GlobeImmune, Inc. today announced that Dr. Alex Franzusoff has been appointed Vice President of Research. Dr. Franzusoff, one of the Company’s three scientific founders, was most recently Associate Professor of Cellular and Developmental Biology at the University of Colorado Health Sciences Center. He received his Ph.D. at the State University of New York at Stony Brook and completed post-doctoral fellowships at the Swiss Federal Institute of Technology (ETH) in Zurich, Switzerland, the European Molecular Biology Laboratories in Heidelberg, Germany and the University of California at Berkeley. In addition to being one of the inventors of the Company’s core yeast immunotherapy technology, Dr. Franzusoff is an expert in the field of viral cell biology and holds a number of patents in this area.
Dr. Timothy Rodell, Chief Executive Officer of GlobeImmune stated: “Alex has been instrumental to the Company’s progress to date and this appointment reflects his key future role in our success.”
GlobeImmune, Inc. is a private company developing products for chronic viral diseases and cancer based on a novel, proprietary immunotherapy platform technology. The Company’s first two products for the treatment of cancers of the lung and gastrointestinal tract and the prevention and treatment of HIV/AIDS are expected to enter human clinical trials in 2004.
GlobeImmune is headquartered at the Fitzsimons BioScience Park in Aurora Colorado.
GlobeImmune, Inc.
12635 E. Montview Blvd.
Aurora, Colorado 80010
720-859-4070